New Enterprise Associates has increased its focus on companies developing drugs for rare disease, an effort that’s paying off. Portfolio company Prosensa Holding BV, which it backed last year, has just gone public on Nasdaq. The company develops therapies for rare conditions such as Duchenne muscular dystrophy, myotonic dystrophy and Huntington’s disease.
To read the full, original article click on this link: Focus on Rare Diseases Pays Off for New Enterprise Associates as Prosensa Goes Public
{iframe}http://pevc.dowjones.com/Article?an=DJFVW00020130701e971aqlz9&cid=32135029&ctype=ts&ReturnUrl=http%3a%2f%2fpevc.dowjones.com%2fArticle%3fan%3dDJFVW00020130701e971aqlz9%26cid%3d32135029%26ctype%3dts{/iframe}